Pfizer Canada Inc. announced today that Health Canada has approved ZELDOX (ziprasidone hydrochloride), for use in the treatment of acute manic or mixed episodes associated with bipolar disorder. Prompt and effective control of acute manic or mixed episodes is an important goal as patients are at an increased risk for impulsive and dangerous behaviors, often requiring psychiatric hospitalization.
The details can be read here.
No comments:
Post a Comment